CBD and ADHD - Is it a Good Combination? Scientific Evidence 2026

Cannabidiol is not a treatment for ADHD, and no study has shown this. The only randomized trial in this indication involved 30 adults, did not achieve its primary endpoint, and the improvement visible in secondary endpoints ceased to be significant after correction for multiple testing. The data that most often accompanies this topic on the internet comes from cannabis surveys, analyses of forum posts, or studies concerning anxiety and insomnia in individuals without a diagnosis of ADHD. This text separates these layers, shows what each study actually measured, and provides the current position of the European regulator regarding the safety of cannabidiol in individuals taking medications. We also explain how a randomized study differs from a survey, as this difference underlies most misunderstandings surrounding this topic. We do not provide dosages: in a disorder treated pharmacologically, the decision is made by the attending physician, not the product description.

KEY INFORMATION
- The Cooper et al. trial on 30 adults with ADHD did not achieve its primary endpoint, which was cognitive performance and activity level in the QbTest (European Neuropsychopharmacology, 2017).
- Improvement in hyperactivity and impulsivity and measures of inhibition was only nominally significant and did not persist after correction for multiple testing. One serious adverse event occurred in the active group.
- A network meta-analysis of 133 double-blind studies indicates methylphenidate as the first-line drug in children and adolescents and amphetamines in adults (Lancet Psychiatry, 2018).
- Heritability of ADHD is estimated at 74%, placing it among disorders with the strongest genetic basis (Molecular Psychiatry, 2019).
- EFSA states that the safety of cannabidiol cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications (EFSA Journal, 2026).

Does CBD treat ADHD?

No. Cannabidiol is not a registered drug for this indication, and the only randomized trial regarding cannabinoids in ADHD did not achieve its primary endpoint. The EMA-C study was conducted from July 2014 to June 2015 on 30 adults with ADHD, randomly assigned to either the active group (15 people) or placebo (15 people). The Sativex preparation was administered as an oral mucosal spray (European Neuropsychopharmacology, 2017).

The primary endpoint was cognitive performance and activity level measured by the QbTest, not the CAARS scale, as many summaries state. In the analysis according to the planned treatment, no significant difference was found, although the result favored the active group (Est=-0.17; 95% CI from -0.40 to 0.07; p=0.16). This is the main result of this study and it determines its significance.

In secondary endpoints, the picture was more interesting but still inconclusive. The preparation was associated with only nominally significant improvement in hyperactivity and impulsivity (p=0.03) and cognitive measure of inhibition (p=0.05), as well as a trend towards improvement in inattention (p=0.10) and emotional instability (p=0.11). After correction for multiple testing, none of these results achieved significance.

The safety was described directly, and this part is often overlooked. In the active group, one serious adverse event occurred in the form of muscle spasms and three mild events, while in the placebo group, one serious cardiovascular event occurred. The authors cautiously summarized the work: it provides preliminary support for the theory of self-medication with cannabis in ADHD and justifies further research on the endocannabinoid system, but it is not conclusive.

Where does ADHD come from and what is known about it?

ADHD is a neurodevelopmental disorder with a strong genetic basis. Decades of family, twin, and adoption studies show that it runs in families, and heritability is estimated at 74%. This value has justified the search for susceptibility genes. Linkage studies have shown that the effect of individual risk variants must be very small, and genome-wide association analyses have indicated several regions of genome-wide significance (Molecular Psychiatry, 2019).

About one-third of heritability is attributed to the polygenic component, composed of many common variants with small effects. From studies on copy number variation, it is also known that rare insertions and deletions account for part of the heritability. These findings have indicated new biological pathways, but so far have not translated into treatment. The formula of lack of discipline or parenting failure has no place in this picture.

The clinical picture itself is often described as stable, but it is a construct that has changed over decades with research on the nature and structure of the disorder. Effective treatment methods based on pharmacotherapy are available, often used together with psychosocial approaches. However, their effectiveness is often questioned, as they may not meet the broader needs of many individuals with ADHD, especially in the long term (The Lancet, 2020).

It is also important what is not included in this description. Non-pharmacological methods have proven to be less effective than previously thought, and scientific and clinical studies are beginning to challenge existing understandings of the causes of ADHD. This is the background against which every supplement proposal, including cannabidiol, should be read.

Is ADHD diagnosed more often today than in the past?

The answer is surprising and comes from updates of the two most comprehensive systematic reviews on the prevalence of ADHD. The authors collected 154 original works, of which 135 entered into multifactorial analysis, and checked whether the year of study affects the estimated prevalence of the disorder. It did not. The geographical location of the study also did not affect it (International Journal of Epidemiology, 2014).

The variability of estimates is explained by something else. It is due to the methodological procedures of individual studies: the diagnostic criteria adopted, the criterion of functional impairment, and the source of information about symptoms. In other words, how much ADHD we find in the population mainly depends on how we define and how we ask, not on when and where we ask.

The authors’ conclusion is unequivocal. Over three decades, there is no evidence of an increase in the number of children in the population who meet the criteria for ADHD, as long as standardized diagnostic procedures are used. The increasing number of diagnoses and treated individuals is therefore a phenomenon of a different kind than an increase in the actual prevalence of the disorder.

For the reader seeking support, this has practical consequences. Statistics presented without a description of the method, especially single percentages presented as fact, say more about the counting method than about the phenomenon. Caution regarding such numbers applies equally when they concern the prevalence of ADHD as when they concern the effectiveness of a supplement.

How effective are the medications used in ADHD?

The reference point is a network meta-analysis including 133 randomized double-blind studies, both published and unpublished. They compared seven drugs with each other or with placebo: amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil. The analysis of efficacy at the point closest to 12 weeks included 10,068 children and adolescents and 8,131 adults (The Lancet Psychiatry, 2018).

In children and adolescents, when assessing symptoms by clinicians, all studied drugs performed better than placebo. In teacher assessments, only methylphenidate and modafinil were better than placebo, which in itself indicates how much the result depends on who is observing. In adults, amphetamines and methylphenidate were better than placebo, as well as bupropion and atomoxetine, while modafinil was not.

Tolerance differed from efficacy. In adults, atomoxetine and methylphenidate were tolerated worse than placebo, as well as modafinil, while amphetamines performed worse in both age groups. The authors indicated methylphenidate as the first-line drug in children and adolescents and amphetamines in adults for short-term treatment, and noted that data for 26 and 52 weeks were insufficient. Cannabidiol is not included in this comparison because there are no studies allowing it to be placed there.

Do surveys and forums resolve anything in this matter?

They resolve very little, but they show the scale of beliefs, which can be confused with evidence. A qualitative analysis of discussions on internet forums covered 268 threads, of which 20% were randomly selected, resulting in 55 threads evaluated by three judges. The final sample included 401 posts that received at least one assignment to previously established topics (PLOS One, 2016).

The distribution of ratings contradicts the formula of widespread enthusiasm. Cannabis was described as beneficial in ADHD in 25% of posts, harmful in 8%, simultaneously beneficial and harmful in 5%, and having no effect in 2%. The predominance of opinions about benefits did not transfer to mood, other mental disorders, or general areas of daily functioning. The authors emphasize that there are no clinical recommendations or systematic studies supporting the beneficial effect of cannabis in ADHD.

The second work in this vein is an online survey among 1738 students, covering measures of ADHD symptoms, cannabis use, and executive dysfunction. Individuals with ADHD who used cannabis reported occasional beneficial effects on many symptoms, including hyperactivity and impulsivity, as well as improvement in most adverse effects of the medications taken (Journal of Attention Disorders, 2022).

The limitations of these works are the same and should be read together with the results. Both describe cannabis, not cannabidiol itself, both rely on declarations, neither has a control group or blinding. The authors of the second one cautiously conclude: the results suggest that individuals with ADHD may use cannabis as a form of self-medication, which is a statement about patient behavior, not about the efficacy of the product.

What is the difference between a randomized study and a survey?

This difference underlies most misunderstandings surrounding CBD and ADHD, and all the works described above illustrate it well. In a randomized and blinded study, assignment to the preparation or placebo is random, and neither the participant nor the evaluator knows who received what. The primary endpoint is established before the start to prevent later selection of the most favorable outcome. This was the setup of the EMA-C trial, and therefore its negative result weighs more than the consistent declarations of hundreds of individuals.

A cross-sectional survey has none of these safeguards. It asks individuals who have decided to use something about how they assess the effect. There is no comparison group, no blinding, and those who have something to say are more likely to respond. The survey among 1738 students and the analysis of 401 posts from forums therefore measure the prevalence of beliefs, not the action of the substance, and their authors state this explicitly.

In the middle stands a retrospective review of documentation, such as the described review of records of 72 patients from a psychiatric clinic. Data comes from clinicians, and symptom severity was measured with validated tools, so the quality of measurement is higher than in a survey. However, there is no control group and blinding, and the preparation was used as an adjunct to standard treatment, so improvement cannot be attributed to one thing.

The consequence for the reader is one. A statement about what percentage helped means nothing in itself until it is known who was asked and what was compared. Three works may provide similar percentages and have completely different evidential weight, and the study design determines this more than the sample size.

Does CBD help with anxiety and insomnia in ADHD?

Here lies the most frequently repeated misunderstanding: data exists, but it comes from outside ADHD. The most frequently cited work is a retrospective review of documentation from a psychiatric clinic, not a randomized study. Records of 103 adults were reviewed, and the final sample included 72 patients: 47 presented mainly due to anxiety, 25 due to poor sleep (The Permanente Journal, 2019).

The results diverged between two areas. Anxiety severity decreased in the first month in 57 individuals, or 79.2%, and remained reduced throughout the observation period. Sleep improvement was noted in the first month in 48 individuals, or 66.7%, but in subsequent months, sleep rates fluctuated. This difference matters because in summaries, both percentages are usually presented as equally durable effects.

The study design limits conclusions more than the numbers themselves. A review of patient records without a control group and without blinding does not allow separating the action of the preparation from the natural course of the ailment or from concurrently conducted treatment, as cannabidiol was used as an adjunct to standard therapy. The authors themselves conclude that controlled clinical trials are needed. None of the patients had a diagnosis of ADHD as the reason for presentation.

The practical consequence is that transferring these results to ADHD is extrapolation, not establishment. If the problem is persistent insomnia or heightened anxiety, the first choice direction remains diagnostics and discussion with the attending physician. Separately, we discuss CBD for insomnia and sleep disorders and why cannabis does not replace depression treatment.

What does EFSA say about the safety of cannabidiol?

The position of the European food regulator is more cautious than the formulas circulating online and directly concerns the reader of this text. The panel reminded that the data gaps indicated in 2022 have not been closed, and a literature search up to June 2024 confirmed their persistence, as many new works have non-standardized protocols, short duration, and concurrent pharmacological treatment of participants (EFSA Journal, 2026).

The reservations are specific. Animal studies have shown consistent liver toxicity, with liver mass and histopathological changes responding earliest. Human studies indicated hepatotoxic potential, especially with concurrent use of other medications. Hormonal disturbances were also noted, including altered thyroid hormone levels, neurodevelopmental effects after prenatal exposure, and a lack of any studies on immunotoxicity.

The panel derived a provisional safe dose of 0.0275 mg per kilogram of body weight per day using the benchmark dose method, with an uncertainty factor of 400, which for a 70 kg person gives about 2 mg per day. This is not a therapeutic recommendation or a dose to be measured for ADHD, but a safety assessment threshold for supplements with at least 98% purity of cannabidiol, without nanoparticles. The repeated formula of safety up to 1500 mg per day has no support in this document, and the address of the review to which it is often attributed has not been operational for a long time.

The closing statement of the assessment has the greatest significance for individuals with ADHD. The safety of cannabidiol cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications concurrently. An adult treated with methylphenidate or atomoxetine belongs to the third of these groups, and a teenager with ADHD belongs to both the first and third groups simultaneously.

What interactions does CBD have with ADHD medications?

Interactions are a real reason why the decision belongs to the attending physician. A compilation of cannabinoid interactions with medications, prepared based on information contained in product characteristics, indicated 57 prescription drugs with a narrow therapeutic index that cannabinoid use may affect, regardless of whether they come from a medicinal product or an over-the-counter extract (Medical Cannabis and Cannabinoids, 2020).

The authors organize this phenomenon by roles, not by brand names. A cannabinoid may inhibit or stimulate the metabolism of another drug, and it may also compete with it for the same metabolic enzyme. The drug whose concentration changes as a result appears in this system as a passive side. A narrow therapeutic index means that the distance between the effective and toxic concentration is small, so even a moderate change in metabolism translates into a change in action.

In addition, EFSA’s determination that the hepatotoxic potential of cannabidiol has been revealed in humans primarily with concurrent use of other medications means that for a person treated for ADHD, the risk does not concern the supplement in isolation but the entire set of medications taken. Assessing this set goes beyond what can be resolved based on the product description.

One warning is more important than all the others and does not depend on pharmacology. Do not discontinue methylphenidate or atomoxetine on your own to make room for cannabidiol. The effectiveness of stimulants in ADHD itself is based on dozens of randomized studies, while that of cannabidiol in this indication is based on one trial that did not achieve its primary endpoint.

Can CBD be given to a child or teenager with ADHD?

Without indication and supervision from a specialist, no. There is no randomized study that has tested isolated cannabidiol in children with ADHD, so the basis for the decision would be solely analogies from other indications. In addition, the regulator’s position states that the safety of cannabidiol cannot be established in individuals under 25 years of age, thus affecting the entire pediatric population and young adults.

The reason for this boundary is not formal. In EFSA’s assessment, neurodevelopmental effects were noted after prenatal exposure, indicating long-term and sex-dependent consequences, as well as the passage of cannabidiol through the placenta and its accumulation in the body. Separately, the panel noted that data on neurological and psychiatric safety are considered insufficient, which is a concern that hits the core in a neurodevelopmental disorder.

What remains instead? In children and adolescents, a network meta-analysis indicates methylphenidate as the first-line drug for short-term treatment, usually used together with psychosocial interventions. It is also worth remembering the caveat from the review in The Lancet that non-pharmacological methods have proven to be less effective than previously thought, so lifestyle changes alone are rarely sufficient.

For parents seeking support outside pharmacotherapy, we recommend two texts that organize the topic without promises: a review of supplements and herbs supporting concentration in ADHD and a summary of what is safe for children and what to avoid. Discuss any changes with the attending psychiatrist or neurologist beforehand.

How much is really known about the absorption of cannabidiol?

Less than suggested by tables comparing forms of administration. A systematic review of the pharmacokinetics of cannabidiol in humans included a search of the PubMed and EMBASE databases, reviewing 792 articles, of which 24 contained pharmacokinetic parameters in humans. This is all the available material on the fate of this molecule in the human body (Frontiers in Pharmacology, 2018).

The most important determination concerns absolute bioavailability, or the percentage of the dose reaching the bloodstream. It was measured only after smoking and was 31%. For no other route of administration has anyone conducted such a measurement in humans, despite the availability of intravenous preparations needed for comparison. Popular comparisons providing the bioavailability of sublingual drops or capsules in percentages are therefore based on values that have not been measured.

The half-life varies significantly depending on the route of administration. After administration to the oral mucosa, it ranged from 1.4 to 10.9 hours, after chronic oral administration from 2 to 5 days, after intravenous administration about 24 hours, and after smoking about 31 hours. The maximum concentration increases with the dose and is reached faster after inhalation than after oral or sublingual administration.

Two observations have direct implications for practice. The maximum concentration is higher after a meal and in preparations with a fat carrier, and the time to reach it falls within a wide range from zero to four hours. The authors close the review with a statement about the lack of data and discrepancies in the described pharmacokinetics, despite the widespread use of cannabidiol by people.

How to recognize a trustworthy CBD product?

The starting point is the awareness that the label may not match the content. An analysis of 80 unregulated cannabis preparations, purchased online and in physical stores, detected delta-9-THC above the limit of quantification in 52 samples, in concentrations ranging from 0.008 to 2.071 mg per milliliter. Twenty-one preparations had a label indicating no THC, yet this compound was detected in five of them (Drug and Alcohol Dependence, 2022).

The authors of this work state the matter plainly: consumers take cannabis preparations without understanding the risk of unintended consumption of delta-9-THC. They list consequences that extend beyond health, including issues related to child custody, driving, employment, and eligibility in sports. For a person with ADHD, who often drives and works professionally, this list is not theoretical.

The practical principle is simple and does not require chemical knowledge. If the seller cannot show a certificate of analysis for the batch you are buying, it is unknown what is in the package. A declaration on the label, a description on the website, or reviews from other buyers do not replace this document, and with concurrent treatment for ADHD, the stakes are higher than just the effectiveness of the product.

Is CBD legal in Poland?

Cannabidiol is not a controlled substance in Poland, but the legal limit concerns the plant, not the finished product. Industrial hemp refers to plants of the species Cannabis sativa L., in which the sum of delta-9-THC and tetrahydrocannabinolic acid in the flowering tops or fruiting, from which the resin has not been removed, does not exceed 0.3% when calculated on a dry mass, with the sum subject to rounding to one decimal place.

The basis is Article 4 point 5 of the Act of July 29, 2005 on Counteracting Drug Addiction (consolidated text Journal of Laws 2023 item 1939), as amended by the Act of March 24, 2022 (Journal of Laws 2022 item 763), in force since May 7, 2022. Citing a publication from 2005 here is a mistake, as the current wording of the provision comes from the 2022 amendment and provides a different threshold value.

Two distinctions are often confused, and both have laboratory consequences. The threshold is calculated as the sum of delta-9-THC and tetrahydrocannabinolic acid, not as delta-9-THC alone, which gives a different measurement result for the same sample. The national threshold corresponds to the EU threshold in terms of value, but it does not derive from it, as these are two separate regulations that independently established the same number.

Legality is not the same as approval for use in ADHD. Products with cannabidiol are sold outside the category of medicinal products, so they have not undergone registration procedures for any psychiatric indication and cannot be advertised for such an indication. Compliance with trade law and proof of effectiveness are two different things.

Frequently Asked Questions

Does CBD treat ADHD?

No. The only randomized trial regarding cannabinoids in ADHD involved 30 adults and did not achieve its primary endpoint, which was cognitive performance and activity level in the QbTest. Improvement in secondary endpoints was only nominally significant and disappeared after correction for multiple testing.

Did Cooper 2017 measure the CAARS scale?

No, and this is a common mistake in summaries. The primary endpoint was the QbTest, assessing cognitive performance and activity level. The result in the analysis according to the planned treatment was not significant (p=0.16). Secondary endpoints included ADHD symptoms and emotional instability.

Can CBD be combined with methylphenidate or atomoxetine?

Only after consulting with the attending physician. The interaction compilation of cannabinoids indicated 57 prescription drugs with a narrow therapeutic index, and EFSA notes that the hepatotoxic potential of cannabidiol has been observed in humans, especially when used concurrently with other medications. Do not discontinue the stimulant on your own.

Does CBD help with insomnia and anxiety in ADHD?

Data comes from outside ADHD. In a review of records of 72 adults from a psychiatric clinic, anxiety severity decreased in the first month in 79.2% of patients and remained reduced, while sleep improvement was noted in 66.7%, but sleep rates fluctuated in subsequent months. No patient had a diagnosis of ADHD.

Does CBD raise dopamine like methylphenidate?

There is no study that has shown this in people with ADHD. Stimulants have dozens of randomized trials in this indication and clear effect sizes, while cannabidiol does not appear in meta-analyses of drugs used in ADHD due to a lack of studies allowing it to be placed there.

Can CBD be given to a child with ADHD?

Without indication and supervision from a specialist, no. There is no randomized study on isolated cannabidiol in children with ADHD, and EFSA states that the safety of cannabidiol cannot be established in individuals under 25 years of age. The panel also noted neurodevelopmental effects after prenatal exposure.

Do cannabis help with ADHD, since patients say so?

Patient declarations describe behavior, not efficacy. In an analysis of 401 posts from forums, cannabis was described as beneficial in ADHD in 25% of posts, harmful in 8%. A survey among 1738 students concerned cannabis, not cannabidiol itself, and was based on self-assessment without a control group.

Is CBD legal in Poland for ADHD?

Cannabidiol is not a controlled substance, and the threshold of 0.3% concerns the sum of delta-9-THC and tetrahydrocannabinolic acid in the plant, according to Article 4 point 5 of the Act on Counteracting Drug Addiction. However, products with cannabidiol are not registered drugs for ADHD and cannot be advertised for this indication.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-04-27 · Updated: 2026-08-10